(0.91%) 5 064.20 points
(0.85%) 38 226 points
(1.51%) 15 841 points
(0.28%) $79.17
(-0.39%) $2.03
(0.03%) $2 310.40
(0.17%) $26.88
(0.32%) $965.70
(-0.02%) $0.932
(-0.09%) $10.98
(-0.06%) $0.797
(-0.02%) $91.11
3 days till quarter result
(amc 2024-05-06)
Expected move: +/- 6.55%
@ $11.63
Išleistas: 2 geg. 2024 @ 20:41
Grąža: -0.22%
Ankstesnis signalas: geg. 2 - 19:36
Ankstesnis signalas:
Grąža: 0.26 %
Live Chart Being Loaded With Signals
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets...
Stats | |
---|---|
Šios dienos apimtis | 6.84M |
Vidutinė apimtis | 9.02M |
Rinkos kapitalizacija | 13.81B |
EPS | $0 ( 2024-02-28 ) |
Kita pelno data | ( $0 ) 2024-05-06 |
Last Dividend | $0.120 ( 2023-11-22 ) |
Next Dividend | $0 ( N/A ) |
P/E | 232.00 |
ATR14 | $0.220 (1.90%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-18 | Le Goff Corinne | Buy | 110 162 | Restricted Stock Units |
2024-04-18 | Le Goff Corinne | Buy | 78 688 | Restricted Stock Units |
2024-04-15 | Le Goff Corinne | Buy | 0 | |
2024-04-02 | Malik Rajiv | Buy | 18 845 | Restricted Stock Units |
2024-03-13 | Mauro Anthony | Sell | 250 000 | Common Stock |
INSIDER POWER |
---|
9.40 |
Last 99 transactions |
Buy: 1 339 847 | Sell: 1 117 278 |
Tūris Koreliacija
Viatris Inc. Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
MMAC | 0.897 |
NETE | 0.888 |
SRAC | 0.833 |
AMRB | 0.83 |
RAVN | 0.829 |
BRKH | 0.824 |
DOOO | 0.824 |
EUSG | 0.819 |
BOCH | 0.817 |
TKNO | 0.816 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
SVOK | -0.94 |
PAIC | -0.907 |
SVAC | -0.9 |
RMRM | -0.883 |
FEYE | -0.846 |
TLGT | -0.841 |
SPRT | -0.83 |
FTOCU | -0.823 |
FTOC | -0.815 |
OPCH | -0.808 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Viatris Inc. Koreliacija - Valiuta/Žaliavos
Viatris Inc. Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $15.38B |
Bruto pelnas: | $6.57B (42.70 %) |
EPS: | $0.0456 |
FY | 2023 |
Pajamos: | $15.38B |
Bruto pelnas: | $6.57B (42.70 %) |
EPS: | $0.0456 |
FY | 2022 |
Pajamos: | $16.26B |
Bruto pelnas: | $6.50B (39.95 %) |
EPS: | $1.710 |
FY | 2021 |
Pajamos: | $17.89B |
Bruto pelnas: | $5.58B (31.17 %) |
EPS: | $-2.11 |
Financial Reports:
No articles found.
Viatris Inc. Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.120 (N/A) |
$0.120 (N/A) |
$0.120 (N/A) |
$0.120 (N/A) |
$0.240 (N/A) |
$0.120 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.00741 | 1986-12-24 |
Last Dividend | $0.120 | 2023-11-22 |
Next Dividend | $0 | N/A |
Payout Date | 2023-12-15 | |
Next Payout Date | N/A | |
# dividends | 88 | -- |
Total Paid Out | $2.99 | -- |
Avg. Dividend % Per Year | 2.32% | -- |
Score | 5.32 | -- |
Div. Sustainability Score | 6.81 | |
Div.Growth Potential Score | 6.62 | |
Div. Directional Score | 6.72 | -- |
Year | Amount | Yield |
---|---|---|
1986 | $0.00741 | 0.28% |
1987 | $0.0148 | 0.88% |
1988 | $0.0111 | 0.86% |
1989 | $0.0148 | 1.13% |
1990 | $0.0222 | 0.63% |
1991 | $0.0296 | 1.01% |
1992 | $0.0326 | 0.53% |
1993 | $0.0416 | 0.46% |
1994 | $0.0564 | 0.78% |
1995 | $0.0652 | 0.85% |
1996 | $0.0712 | 0.70% |
1997 | $0.0712 | 0.97% |
1998 | $0.0712 | 0.80% |
1999 | $0.0712 | 0.53% |
2000 | $0.0712 | 0.66% |
2001 | $0.0712 | 0.65% |
2002 | $0.0756 | 0.47% |
2003 | $0.0966 | 0.61% |
2004 | $0.120 | 0.48% |
2005 | $0.210 | 1.20% |
2006 | $0.240 | 1.20% |
2007 | $0.120 | 0.60% |
2008 | $0 | 0.00% |
2009 | $0 | 0.00% |
2010 | $0 | 0.00% |
2011 | $0 | 0.00% |
2012 | $0 | 0.00% |
2013 | $0 | 0.00% |
2014 | $0 | 0.00% |
2015 | $0 | 0.00% |
2016 | $0 | 0.00% |
2017 | $0 | 0.00% |
2018 | $0 | 0.00% |
2019 | $0 | 0.00% |
2020 | $0 | 0.00% |
2021 | $0.330 | 1.78% |
2022 | $0.480 | 3.38% |
2023 | $0.600 | 5.27% |
2024 | $0 | 0.00% |
With a moderate Dividend Sustainability Score (DSS), the company may sustain its dividends, but continuous monitoring is advised for any financial shifts. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Diamond | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.00355 | 1.500 | 9.93 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.00115 | 1.200 | 9.96 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.00263 | 1.500 | -1.082 | -1.623 | [0.1 - 1] |
payoutRatioTTM | 10.52 | -1.000 | 10.00 | -10.00 | [0 - 1] |
currentRatioTTM | 1.572 | 0.800 | 7.14 | 5.71 | [1 - 3] |
quickRatioTTM | 0.658 | 0.800 | -0.833 | -0.666 | [0.8 - 2.5] |
cashRatioTTM | 0.128 | 1.500 | -0.401 | -0.602 | [0.2 - 2] |
debtRatioTTM | 0.382 | -1.500 | 3.63 | -5.45 | [0 - 0.6] |
interestCoverageTTM | 1.886 | 1.000 | -0.413 | -0.413 | [3 - 30] |
operatingCashFlowPerShareTTM | 2.33 | 2.00 | 9.22 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 1.937 | 2.00 | 9.03 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.890 | -1.500 | 6.44 | -9.66 | [0 - 2.5] |
grossProfitMarginTTM | 0.419 | 1.000 | 6.36 | 6.36 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.0708 | 1.000 | -0.585 | -0.585 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.154 | 1.000 | -0.257 | -0.257 | [0.2 - 2] |
assetTurnoverTTM | 0.323 | 0.800 | -1.178 | -0.943 | [0.5 - 2] |
Total Score | 6.81 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 255.16 | 1.000 | 10.00 | 0 | [1 - 100] |
returnOnEquityTTM | 0.00263 | 2.50 | -0.695 | -1.623 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 1.937 | 2.00 | 9.35 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 4.13 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 2.33 | 2.00 | 9.22 | 10.00 | [0 - 30] |
payoutRatioTTM | 10.52 | 1.500 | 10.00 | -10.00 | [0 - 1] |
pegRatioTTM | 43.66 | 1.500 | 10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.182 | 1.000 | 7.96 | 0 | [0.1 - 0.5] |
Total Score | 6.62 |
Viatris Inc.
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.